Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination

Cerus Corporation, Concord, California 94520, USA.
Transfusion (Impact Factor: 3.23). 07/2007; 47(6):1062-70. DOI: 10.1111/j.1537-2995.2007.01237.x
Source: PubMed


The human erythrovirus B19 (B19) is a small (18- to 26-nm) nonenveloped virus with a single-stranded DNA genome of 5.6 kb. B19 is clinically significant and is also generally resistant to pathogen inactivation methods. Photochemical treatment (PCT) with amotosalen and ultraviolet A (UVA) inactivates viruses, bacteria, and protozoa in platelets (PLTs) and plasma prepared for transfusion. In this study, the capacity of PCT to inactivate B19 in human PLT concentrates was evaluated.
B19 inactivation was measured by a novel enzyme-linked immunosorbent spot (ELISPOT) erythroid progenitor cell infectivity assay and by inhibition of long-range (up to 4.3 kb) polymerase chain reaction (PCR), under conditions where the whole coding region of the viral genome was amplified. B19-infected plasma was used to test whether incubation of amotosalen with virus before PCT enhanced inactivation compared to immediate PCT.
Inactivation of up to 5.8 log of B19 as measured by the infectivity assay, or up to 6 logs as measured by PCR inhibition can be achieved under non-limiting conditions. Inactivation efficacy was found to increase with incubation prior to UVA illumination. Without incubation prior to illumination 2.1 +0.4 log was inactivated as determined by infectivity assay. When measured by PCR inhibition, inactivation varied inversely with amplicon size. When primers that spanned the entire coding region of the B19 genome were used, maximum inhibition of PCR amplification was demonstrated.
Under defined conditions, PCT with amotosalen combined with UVA light can be used to inactivate B19, a clinically significant virus that can be transmitted through blood transfusion, and heretofore has been demonstrated to be refractory to inactivation.

7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Both transmit and receive diversities are employed to establish independent wireless channels in the same bandwidth and the same time for increasing the spectrum efficiency between two localized transceivers. We study five approaches to determine the antenna weights. Among them, a novel SVD-MMSE approach is proven to achieve the best system performance
    Vehicular Technology Conference, 1999 IEEE 49th; 08/1999
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Remarkable improvements have been made in blood safety since the onset of the HIV epidemic. However, the current paradigm does not prevent all transfusion-transmitted infections and is reactive to new agents, thus accepting that some patients may be harmed before preventive measures are introduced. Several methods are now available that selectively damage DNA and RNA, thus inactivating pathogens contaminating blood components while not damaging the cells or plasma proteins of the blood component. Clinical trials have been completed and pathogen-inactivated platelets and plasma are widely used in Europe. A recent consensus conference recommended implementation of pathogen inactivation when a feasible and fe method is available that inactivates a broad spectrum of pathogens. The shortcomings of our present paradigm for preventing transfusion-transmitted diseases are described, along with a summary of the status of pathogen inactivation.
    American Journal of Clinical Pathology 01/2008; 128(6):945-55. DOI:10.1309/RAPQ3NXG3MV9AL94 · 2.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Platelet storage and availability for the purposes of transfusion are currently restricted by a markedly short shelf life of 5 to 7 days owing to an increased risk of bacterial growth and storage-related deterioration called the platelet storage lesion. Because most bacteria grow to confluence within 5 days during storage at room temperature, there is little increased risk of bacterial overgrowth with testing in place, and the only remaining issue is the quality of platelets during the extended storage. Although the manifestations of the storage lesion have been well studied using a variety of in vitro measures, the precise biochemical pathways involved in the initiation and progression of this process have yet to be identified. Proteomics has emerged as a powerful tool to identify and monitor changes during platelet storage and, in combination with biochemical and physiologic studies, facilitates the development of a sophisticated mechanistic view. In this review, we summarize recent experimental work that has led to a detailed overview of protein changes linked to platelet functions and signaling pathways, providing potential targets for inhibitors to ameliorate the storage lesion.
    Transfusion medicine reviews 11/2008; 22(4):268-79. DOI:10.1016/j.tmrv.2008.05.004 · 2.92 Impact Factor
Show more